Genetics and Treatment of Dystonia

Neurologic Clinics

Volumn 27, Issue 3, 2009, Pages 697-718

  Schwarz, Cordelia S ^a   Bressman, Susan B ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Basal ganglia; Botulinum toxin; Deep brain stimulation; Dystonia; DYT1; Genetics

Indexed keywords

ALPHA SARCOGLYCAN; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CYCLOBENZAPRINE; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; EPSILON SARCOGLYCAN; GAMMA SARCOGLYCAN; LEVODOPA; LORAZEPAM; MEXILETINE; MORPHINE SULFATE; OXYBATE SODIUM; PARKIN; PENICILLAMINE; SEPIAPTERIN REDUCTASE; TETRATHIOMOLYBDIC ACID; TIZANIDINE; TRIENTINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; ZINC; ZOLPIDEM;

AMINO ACID SUBSTITUTION; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BLEPHAROSPASM; BRAIN DEPTH STIMULATION; CERVICAL DYSTONIA; CHOREOATHETOSIS; CLINICAL TRIAL; CONFUSION; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DYSPHAGIA; DYSTONIA; FOCAL DYSTONIA; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC COUNSELING; HALLUCINATION; HUMAN; INJECTION SITE PAIN; LOW DRUG DOSE; MEMORY DISORDER; MULTIFOCAL DYSTONIA; MYOCLONUS DYSTONIA; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOSIS; PATHOPHYSIOLOGY; PENETRANCE; PHENOTYPE; PHYSIOTHERAPY; PRIORITY JOURNAL; RAPID ONSET DYSTONIA PARKINSONISM; REVIEW; SEDATION; SEGAWA DISEASE; SEGMENTAL DYSTONIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY RESISTANCE; TORSION DYSTONIA; WILSON DISEASE; X LINKED DYSTONIA PARKINSONISM; XEROSTOMIA;

AGE OF ONSET; ANIMALS; APOPTOSIS REGULATORY PROTEINS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DYSTONIA; DYSTONIA MUSCULORUM DEFORMANS; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR CHAPERONES; MUTATION; MYOCLONUS; NUCLEAR PROTEINS; PARKINSONIAN DISORDERS; PHENOTYPE; PROGNOSIS;

EID: 67449149588     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2009.04.010     Document Type: Review

References (119)

1. Fahn S. Concept and classification of dystonia. Adv Neurol 50 (1988) 1-8
2. Ozelius L.J., Hewett J.W., Page C.E., et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 17 (1997) 40-48
3. Nolte D., Niemann S., and Muller U. Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism. Proc Natl Acad Sci U S A 100 (2003) 10347-10352
4. Ichinose H., Ohye T., Takahashi E., et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 8 (1994) 236-242
5. Asmus F., Zimprich A., Tezenas Du Montcel S., et al. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 52 (2002) 489-492
6. Brashear A., Dobyns W.B., de Carvalho Aguiar P., et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 130 (2007) 828-835
7. Gimenez-Roldan S., Delgado G., Marin M., et al. Hereditary torsion dystonia in gypsies. Adv Neurol 50 (1988) 73-81
8. Parker N. Hereditary whispering dysphonia. J Neurol Neurosurg Psychiatry 48 (1985) 218-224
9. Leung J.C., Klein C., Friedman J., et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics 3 (2001) 133-143
10. Kabakci K., Hedrich K., Leung J.C., et al. Mutations in DYT1: Extension of the phenotypic and mutational spectrum. Neurology 62 (2004) 395-400
11. Zirn B., Grundmann K., Huppke P., et al. Novel TOR1A mutation p.Arg288Gln in early-onset dystonia (DYT1). J Neurol Neurosurg Psychiatry 79 (2008) 1327-1330
12. Vale R.D. AAA proteins. Lords of the ring. J Cell Biol 150 (2000) F13-F19
13. Hanson P.I., and Whiteheart S.W. AAA+ proteins: have engine, will work. Nat Rev Mol Cell Biol 6 (2005) 519-529
14. Goodchild R.E., and Dauer W.T. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. Proc Natl Acad Sci U S A 101 (2004) 847-852
15. Hewett J.W., Zeng J., Niland B.P., et al. Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiol Dis 22 (2006) 98-111
16. Giles L.M., Chen J., Li L., et al. Dystonia-associated mutations cause premature degradation of torsinA protein and cell-type-specific mislocalization to the nuclear envelope. Hum Mol Genet 17 (2008) 2712-2722
17. McNaught K.S., Kapustin A., Jackson T., et al. Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol 56 (2004) 540-547
18. Shashidharan P., Sandu D., Potla U., et al. Transgenic mouse model of early-onset DYT1 dystonia. Hum Mol Genet 14 (2005) 125-133
19. Sharma N., Baxter M.G., Petravicz J., et al. Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J Neurosci 25 (2005) 5351-5355
20. Dang M.T., Yokoi F., McNaught K.S., et al. Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia. Exp Neurol 196 (2005) 452-463
21. Dang M.T., Yokoi F., Pence M.A., et al. Motor deficits and hyperactivity in Dyt1 knockdown mice. Neurosci Res 56 (2006) 470-474
22. Kock N., Naismith T.V., Boston H.E., et al. Effects of genetic variations in the dystonia protein torsinA: identification of polymorphism at residue 216 as protein modifier. Hum Mol Genet 15 (2006) 1355-1364
23. Risch N.J., Bressman S.B., Senthil G., et al. Intragenic cis and trans modification of genetic susceptibility in DYT1 torsion dystonia. Am J Hum Genet 80 (2007) 1188-1193
24. Sibbing D., Asmus F., Konig I.R., et al. Candidate gene studies in focal dystonia. Neurology 61 (2003) 1097-1101
25. Kamm C., Asmus F., Mueller J., et al. Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia. Neurology 67 (2006) 1857-1859
26. Bressman S.B., Sabatti C., Raymond D., et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 54 (2000) 1746-1752
27. Fasano A., Nardocci N., Elia A.E., et al. Non-DYT1 early-onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature. Mov Disord 21 (2006) 1411-1418
28. Leube B., Kessler K.R., Ferbert A., et al. Phenotypic variability of the DYT1 mutation in German dystonia patients. Acta Neurol Scand 99 (1999) 248-251
29. Koukouni V., Martino D., Arabia G., et al. The entity of young onset primary cervical dystonia. Mov Disord 22 (2007) 843-847
30. Jamora R.D., Tan E.K., Liu C.P., et al. DYT1 mutations amongst adult primary dystonia patients in Singapore with review of literature comparing east and west. J Neurol Sci 247 (2006) 35-37
31. Risch N., de Leon D., Ozelius L., et al. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet 9 (1995) 152-159
32. Frederic M., Lucarz E., Monino C., et al. First determination of the incidence of the unique TOR1A gene mutation, c.907delGAG, in a Mediterranean population. Mov Disord 22 (2007) 884-888
33. Zeman W., and Dyken P. Dystonia musculorum deformans. Clinical, genetic and pathoanatomical studies. Psychiatr Neurol Neurochir 70 (1967) 77-121
34. Heiman G.A., Ottman R., Saunders-Pullman R.J., et al. Increased risk for recurrent major depression in DYT1 dystonia mutation carriers. Neurology 63 (2004) 631-637
35. Heiman G.A., Ottman R., Saunders-Pullman R.J., et al. Obsessive-compulsive disorder is not a clinical manifestation of the DYT1 dystonia gene. Am J Med Genet B Neuropsychiatr Genet 144 (2007) 361-364
36. Ghilardi M.F., Carbon M., Silvestri G., et al. Impaired sequence learning in carriers of the DYT1 dystonia mutation. Ann Neurol 54 (2003) 102-109
37. Bressman S.B., Raymond D., Wendt K., et al. Diagnostic criteria for dystonia in DYT1 families. Neurology 59 (2002) 1780-1782
38. Eidelberg D., Moeller J.R., Antonini A., et al. Functional brain networks in DYT1 dystonia. Ann Neurol 44 (1998) 303-312
39. Asanuma K., Ma Y., Okulski J., et al. Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 64 (2005) 347-349
40. Carbon M., Kingsley P.B., Su S., et al. Microstructural white matter changes in carriers of the DYT1 gene mutation. Ann Neurol 56 (2004) 283-286
41. Edwards M.J., Huang Y.Z., Wood N.W., et al. Different patterns of electrophysiological deficits in manifesting and non-manifesting carriers of the DYT1 gene mutation. Brain 126 (2003) 2074-2080
42. Fiorio M., Gambarin M., Valente E.M., et al. Defective temporal processing of sensory stimuli in DYT1 mutation carriers: a new endophenotype of dystonia?. Brain 130 (2007) 134-142
43. Almasy L., Bressman S.B., Raymond D., et al. Idiopathic torsion dystonia linked to chromosome 8 in two mennonite families. Ann Neurol 42 (1997) 670-673
44. Valente E.M., Bentivoglio A.R., Cassetta E., et al. Identification of a novel primary torsion dystonia locus (DYT13) on chromosome 1p36 in an Italian family with cranial-cervical or upper limb onset. Neurol Sci 22 (2001) 95-96
45. Chouery E., Kfoury J., Delague V., et al. A novel locus for autosomal recessive primary torsion dystonia (DYT17) maps to 20p11.22-q13.12. Neurogenetics 9 (2008) 287-293
46. Fuchs T., Gavarini S., Saunders-Pullman R., et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet 41 (2009) 286-288
47. Bressman S.B., Raymond D., Fuchs T., et al. Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study. Lancet Neurol 8 5 (2009) 441-446
48. Bressman S.B., Warner T.T., Almasy L., et al. Exclusion of the DYT1 locus in familial torticollis. Ann Neurol 40 (1996) 681-684
49. Munchau A., Valente E.M., Davis M.B., et al. A Yorkshire family with adult-onset cranio-cervical primary torsion dystonia. Mov Disord 15 (2000) 954-959
50. Leube B., Rudnicki D., Ratzlaff T., et al. Idiopathic torsion dystonia: assignment of a gene to chromosome 18p in a German family with adult onset, autosomal dominant inheritance and purely focal distribution. Hum Mol Genet 5 (1996) 1673-1677
51. Jarman P.R., del Grosso N., Valente E.M., et al. Primary torsion dystonia: the search for genes is not over. J Neurol Neurosurg Psychiatry 67 (1999) 395-397
52. Placzek M.R., Misbahuddin A., Chaudhuri K.R., et al. Cervical dystonia is associated with a polymorphism in the dopamine (D5) receptor gene. J Neurol Neurosurg Psychiatry 71 (2001) 262-264
53. Misbahuddin A., Placzek M.R., Chaudhuri K.R., et al. A polymorphism in the dopamine receptor DRD5 is associated with blepharospasm. Neurology 58 (2002) 124-126
54. Clarimon J., Brancati F., Peckham E., et al. Assessing the role of DRD5 and DYT1 in two different case-control series with primary blepharospasm. Mov Disord 22 (2007) 162-166
55. Clarimon J., Asgeirsson H., Singleton A., et al. Torsin A haplotype predisposes to idiopathic dystonia. Ann Neurol 57 (2005) 765-767
56. Hague S., Klaffke S., Clarimon J., et al. Lack of association with torsinA haplotype in German patients with sporadic dystonia. Neurology 66 (2006) 951-952
57. Nygaard T.G., Takahashi H., Heiman G.A., et al. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia. Ann Neurol 32 (1992) 603-608
58. Van Hove J.L., Steyaert J., Matthijs G., et al. Expanded motor and psychiatric phenotype in autosomal dominant Segawa syndrome due to GTP cyclohydrolase deficiency. J Neurol Neurosurg Psychiatry 77 (2006) 18-23
59. Steinberger D., Topka H., Fischer D., et al. GCH1 mutation in a patient with adult-onset oromandibular dystonia. Neurology 52 (1999) 877-879
60. Nygaard T.G., Waran S.P., Levine R.A., et al. Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol 11 (1994) 236-240
61. Furukawa Y., Kish S.J., and Lang A.E. Scoliosis in a dopa-responsive dystonia family with a mutation of the GTP cyclohydrolase I gene. Neurology 54 (2000) 2187
62. Kong C.K., Ko C.H., Tong S.F., et al. Atypical presentation of dopa-responsive dystonia: generalized hypotonia and proximal weakness. Neurology 57 (2001) 1121-1124
63. Jarman P.R., Bandmann O., Marsden C.D., et al. GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs. J Neurol Neurosurg Psychiatry 63 (1997) 304-308
64. Hagenah J., Saunders-Pullman R., Hedrich K., et al. High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology 64 (2005) 908-911
65. Ichinose H., Suzuki T., Inagaki H., et al. Molecular genetics of dopa-responsive dystonia. Biol Chem 380 (1999) 1355-1364
66. Furukawa Y., Lang A.E., Trugman J.M., et al. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology 50 (1998) 1015-1020
67. Furukawa Y. Update on dopa-responsive dystonia: locus heterogeneity and biochemical features. Adv Neurol 94 (2004) 127-138
68. van den Heuvel L.P., Luiten B., Smeitink J.A., et al. A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the dutch population. Hum Genet 102 (1998) 644-646
69. Hanihara T., Inoue K., Kawanishi C., et al. 6-Pyruvoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study. Mov Disord 12 (1997) 408-411
70. Steinberger D., Blau N., Goriuonov D., et al. Heterozygous mutation in 5'-untranslated region of sepiapterin reductase gene (SPR) in a patient with dopa-responsive dystonia. Neurogenetics 5 (2004) 187-190
71. Tassin J., Durr A., Bonnet A.M., et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?. Brain 123 Pt 6 (2000) 1112-1121
72. Khan N.L., Graham E., Critchley P., et al. Parkin disease: a phenotypic study of a large case series. Brain 126 (2003) 1279-1292
73. Obeso J.A., Rothwell J.C., Lang A.E., et al. Myoclonic dystonia. Neurology 33 (1983) 825-830
74. Nygaard T.G., Raymond D., Chen C., et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol 46 (1999) 794-798
75. Vidailhet M., Tassin J., Durif F., et al. A major locus for several phenotypes of myoclonus-dystonia on chromosome 7q. Neurology 56 (2001) 1213-1216
76. Zimprich A., Grabowski M., Asmus F., et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 29 (2001) 66-69
77. Asmus F., Hjermind L.E., Dupont E., et al. Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype. Brain 130 (2007) 2736-2745
78. Grunewald A., Djarmati A., Lohmann-Hedrich K., et al. Myoclonus-dystonia: significance of large SGCE deletions. Hum Mutat 29 (2008) 331-332
79. Guettard E., Portnoi M.F., Lohmann-Hedrich K., et al. Myoclonus-dystonia due to maternal uniparental disomy. Arch Neurol 65 (2008) 1380-1385
80. Muller B., Hedrich K., Kock N., et al. Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. Am J Hum Genet 71 (2002) 1303-1311
81. Grabowski M., Zimprich A., Lorenz-Depiereux B., et al. The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur J Hum Genet 11 (2003) 138-144
82. Han F., Racacho L., Lang A.E., et al. Refinement of the DYT15 locus in myoclonus dystonia. Mov Disord 22 (2007) 888-892
83. Kyllerman M., Forsgren L., Sanner G., et al. Alcohol-responsive myoclonic dystonia in a large family: dominant inheritance and phenotypic variation. Mov Disord 5 (1990) 270-279
84. Marelli C., Canafoglia L., Zibordi F., et al. A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome. Mov Disord 23 (2008) 2041-2048
85. Saunders-Pullman R., Shriberg J., Heiman G., et al. Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology 58 (2002) 242-245
86. McKeon A., Ozelius L.J., Hardiman O., et al. Heterogeneity of presentation and outcome in the Irish rapid-onset dystonia-parkinsonism kindred. Mov Disord 22 (2007) 1325-1327
87. + -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron 43 (2004) 169-175
88. Lee L.V., Pascasio F.M., Fuentes F.D., et al. Torsion dystonia in Panay, Philippines. Adv Neurol 14 (1976) 137-151
89. Evidente V.G., Gwinn-Hardy K., Hardy J., et al. X-linked dystonia ("Lubag") presenting predominantly with parkinsonism: a more benign phenotype?. Mov Disord 17 (2002) 200-202
90. Evidente V.G., Advincula J., Esteban R., et al. Phenomenology of "Lubag" or X-linked dystonia-parkinsonism. Mov Disord 17 (2002) 1271-1277
91. Evidente V.G., Nolte D., Niemann S., et al. Phenotypic and molecular analyses of X-linked dystonia-parkinsonism ("lubag") in women. Arch Neurol 61 (2004) 1956-1959
92. Waters C.H., Takahashi H., Wilhelmsen K.C., et al. Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women. Neurology 43 (1993) 1555-1558
93. Waters C.H., Faust P.L., Powers J., et al. Neuropathology of lubag (x-linked dystonia parkinsonism). Mov Disord 8 (1993) 387-390
94. Goto S., Lee L.V., Munoz E.L., et al. Functional anatomy of the basal ganglia in X-linked recessive dystonia-parkinsonism. Ann Neurol 58 (2005) 7-17
95. Brewer G.J., Askari F., Lorincz M.T., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63 (2006) 521-527
96. Simpson D.M., Blitzer A., Brashear A., et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70 (2008) 1699-1706
97. Pappert E.J., Germanson T., and Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 23 (2008) 510-517
98. Jankovic J., Hunter C., Dolimbek B.Z., et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67 (2006) 2233-2235
99. Dressler D., and Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J Neurol 252 (2005) 904-907
100. Luciano M.S., Ozelius L., Sims K., et al. Responsiveness to levodopa in epsilon-sarcoglycan deletions. Mov Disord 24 (2009) 425-428
101. Karp B.I., Goldstein S.R., Chen R., et al. An open trial of clozapine for dystonia. Mov Disord 14 (1999) 652-657
102. Kenney C., and Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 6 (2006) 7-17
103. Kenney C., Hunter C., and Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 22 (2007) 193-197
104. Greene P., Shale H., and Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 3 (1988) 46-60
105. Burke R.E., Fahn S., and Marsden C.D. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36 (1986) 160-164
106. Woon K., Tsegaye M., and Vloeberghs M.H. The role of intrathecal baclofen in the management of primary and secondary dystonia in children. Br J Neurosurg 21 (2007) 355-358
107. Frucht S.J., Houghton W.C., Bordelon Y., et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 65 (2005) 1967-1969
108. Evidente V.G. Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome. Neurology 58 (2002) 662-663
109. Vidailhet M., Vercueil L., Houeto J.L., et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol 6 (2007) 223-229
110. Isaias I.U., Alterman R.L., and Tagliati M. Outcome predictors of pallidal stimulation in patients with primary dystonia: The role of disease duration. Brain 131 (2008) 1895-1902
111. Mueller J., Skogseid I.M., Benecke R., et al. Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: results from a prospective, randomized sham-controlled trial. Mov Disord 23 (2008) 131-134
112. Kiss Z.H., Doig-Beyaert K., Eliasziw M., et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 130 (2007) 2879-2886
113. Pretto T.E., Dalvi A., Kang U.J., et al. A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg 109 (2008) 405-409
114. Moro E., Piboolnurak P., Arenovich T., et al. Pallidal stimulation in cervical dystonia: clinical implications of acute changes in stimulation parameters. Eur J Neurol 16 (2009) 506-512
115. Alterman R.L., Miravite J., Weisz D., et al. Sixty hertz pallidal deep brain stimulation for primary torsion dystonia. Neurology 69 (2007) 681-688
116. Blomstedt P., Fytagoridis A., and Tisch S. Deep brain stimulation of the posterior subthalamic area in the treatment of tremor. Acta Neurochir (Wien) 151 (2009) 31-36
117. Moll C.K., Hamel W., Ostertag C.B., et al. Subthalamotomy in cervical dystonia: a case study of lesion location and clinical outcome. Mov Disord 23 (2008) 1751-1756
118. Kim M.J., Jeon S.R., Yoo H.W., et al. Effect of thalamotomy on focal hand dystonia in a family with DYT1 mutation. Mov Disord 23 (2008) 2251-2255
119. Kuncel A.M., Turner D.A., Ozelius L.J., et al. Myoclonus and tremor response to thalamic deep brain stimulation parameters in a patient with inherited myoclonus-dystonia syndrome. Clin Neurol Neurosurg 111 (2009) 303-306